$BCEL

Atreca Inc

  • NASDAQ
  • Miscellaneous Commercial Services
  • Commercial Services
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$2.79 ▲1.825%

Extented Hours

VOLUME

208,013

DAY RANGE

2.6 - 2.78

52 WEEK

1.51 - 7

Join Discuss about BCEL with like-minded investors

SO
@soheil.n #StockTraders.NET
recently

$BCEL - headache free trade that totally missed.

141 Replies 6 👍 15 🔥

SO
@soheil.n #StockTraders.NET
recently

main watch: $OXY, $BBBY...others: $NINE, $BTU, $BCEL

94 Replies 15 👍 13 🔥

profile
@singletary #StockTraders.NET
recently

$bcel nuts on the fails. I piked it lol

121 Replies 11 👍 14 🔥

SO
@soheil.n #StockTraders.NET
recently

$BCEl madness

104 Replies 12 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

$BCEL on monday

74 Replies 7 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

$Bcel for next week

118 Replies 7 👍 10 🔥

profile
@dros #droscrew
recently

hmmm that BCEL

119 Replies 10 👍 12 🔥

profile
@dros #droscrew
recently

993k $BCEL @ 5.2

118 Replies 14 👍 11 🔥

HA
@Hatta2021 #LWT Trading
recently

liked the vid. any chance you can do one on BCEL and some other pharma's?

52 Replies 9 👍 11 🔥

profile
@dros #droscrew
recently

+Initiations 2/8: $AAPL $AFRM $ALDX $BCEL $BTRS $ELDN $HIMS $HSIC $MIRM $MSGM $POSH $SRAX $TFFP $VSEC $WOOF $ZYME . -Initiations 2/8: $OMP

71 Replies 14 👍 8 🔥

Key Metrics

Market Cap

84.47 M

Beta

1.34

Avg. Volume

193.35 K

Shares Outstanding

31.88 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-02

Next Dividend Date

Company Information

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as its lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients.

CEO: John Orwin

Website:

HQ: 450 East Jamie Court South San Francisco, 94080 California

Related News